




Changing the Face of Lung Cancer



hillcrest
Medical Center
utica park clinic
CELEBRATING 40 YEARS



Why Are We Here?




As a community, we
believe we
can do better.

22%

U.S. average 5-year survival
rate for all stages*


* Lung Cancer Survival Rate 2021: <https://seer.cancer.gov/statfacts/html/lungb.html>. Accessed December 14, 2021



Every 2.5 min

- ▶ Someone in the US is diagnosed with lung cancer

Which means...



Oklahoma Lung Cancer Statistics

20% 5-year survival rate

US average: 25%

- We rank 46/50

22% of cases diagnosed at an early stage


US average: 26%

- We rank 47/50

23% do not receive treatment

US average: 20.6%

- We rank 41/50



And yet...

5.4 months

Average time from lung nodule detection to diagnosis¹

70 days


Average time from radiologic diagnosis to intervention²

2.1

Average invasive procedures prior to diagnosis³

(Biopsies, EBUS staging, and/or mediastinoscopy)

The lung cancer patient pathway today



The current process could take weeks, if not months until intervention

There's a better way...



1. Lung Cancer Screening

How many of you know...

- ▶ Current or former smoker who quit in last 15 years
- ▶ 50-80 years old
- ▶ Smoking history of at least 20 pack years



2. Incidental Nodule Pathway

- ▶ 93% of nodules are discovered incidentally
 - ▶ 70% of these nodules are not managed according to evidence based guidelines
- ▶ 2.5% of lung CTs have an incidental finding (>6mm)
 - ▶ >90% require additional imaging
 - ▶ 20% require a procedure
 - ▶ 8-10% are lung cancer
- ▶ Software for nodule tracking
- ▶ Dedicated nodule clinic
- ▶ Patient centered

3. Support



UPC Pulmonary
now with 7
Pulmonologists
and 1 Nurse
Practitioner



Additional
Pulmonologists
joining 07/2024
and 07/2025



Expanded
procedure
space



Expanded
support staff
training



Multidisciplinary
decisions




Education





4. Technology: Shape-Sensing Robotic Endoluminal System ION






- ▶ Ability to reach lesions we were unable to access
- ▶ One procedure: Diagnose and stage
- ▶ Minimally invasive
- ▶ Outpatient procedure



- UPC Pulmonary with 470 Ion cases as of TODAY
- 1st facility in the southwestern US with a 2nd system!
- 1st facility within Ardent with a 2nd system!

- OR Pulmonary Suite + Endoscopy Suite!
- Newly trained staff!
- Growing Pulmonary team!

Leading the STATE!




Single-Physician Unpublished Experience

Ion Endoluminal System Data

Dr. Rachael Pattison: Percentage of Diagnosis, first 115 cases


0 < 2 cm Lesions
percentages



98.4

N= 64
Avg. size:
1.33 cm

≥2 cm Lesions
percentages



96.1

N= 51
Avg. size:
3.17 cm

Ion endoluminal system (N = 115)

Data for Rachael Pattison was provided by the physician or sourced from Ion system logs for the following date range(s): 06/2022 to 09/2023 for Ion endoluminal system data.
The Ion endoluminal system data is being compared to publication data. The follow-up time period of physician-reported data may be variable and is not consistent and not available.
ENB = Electromagnetic navigation bronchoscopy


Single-Physician Unpublished Experience with Ion Endoluminal System Dr. Rachael Pattison

Average Lesion Size


2.10 cm

Percent of diagnosis


% of total



Lesion Count Based on Size



Lesion Distribution



26.8%

Dr. Rachael Pattison provided data for 06/2022 to 09/2023 for Ion endoluminal system data.

The Ion endoluminal system data is being compared to publication data. The follow-up time period of physician reported data may be variable and is not consistent and not available.


Percentage of diagnosis may differ by publication.

1. Folch EE, Pritchett MA, Nead MA, et al. Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study. J Thorac Oncol 2019;14:445-58. <https://doi.org/10.1016/j.jtho.2018.11.013>


Single-physician unpublished experience Ion endoluminal system data compared to published results for TTNB

Dr. Rachael Pattison: Patient Outcomes


Pneumothorax (%) (percentages)



Pneumothorax with Chest Tube (%) (percentages)



Hemorrhage (%) (percentages)



■ Ion endoluminal system (N = 115)

■ Transthoracic Needle Biopsy(Huo, et al.² and Weiner, et al.³) (N = 23,104)


Dr. Rachael Pattison provided data for 06/2022 to 09/2023 for Ion endoluminal system data. The Ion endoluminal system data is being compared to publication data. The follow-up time period of physician reported data may be variable and is not consistent and not available.

TTNB= Transthoracic Needle Biopsy.

2. Huo YR, Chan MV, Habib AR, Lui I, Ridley L. Pneumothorax rates in CT-Guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors. Br J Radiol. 2020 Apr 1;93(1108):20190866. Epub 2020 Jan 3. PMID: 31860329; PMCID: PMC7362905. <https://doi.org/10.1259/bjr.20190866>

3. Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary lesion: an analysis of discharge records. Ann Intern Med. 2011;155(3):137-144. <https://doi.org/10.7326/0003-4819-155-3-201108020-00003>

The lung cancer patient pathway we're building



Goal = Single Anesthesia Diagnose → Stage → Treat




Alberto E Revelo · 2nd
Interventional Pulmonology and Critical Care
Medicine at Ohio State University Compreh...
2w · Edited · 🌐

+ Follow

Lung cancer diagnosis to treatment time: 0 days!


...see more






Changing the Face of Lung Cancer:
Stage Shift = SURVIVAL

Oklahoma Lung Cancer Trends in Stage at Diagnosis



	2014	2015	2016	2017	2018	2019
Localized	17.8%	18.9%	19.6%	21.9%	24.3%	23.1%
Regional	20.9%	21.0%	22.1%	21.1%	19.2%	20.2%
Distant	47.4%	48.5%	43.9%	43.2%	42.6%	42.3%
Unknown	13.8%	11.6%	14.2%	13.6%	13.8%	14.2%

Lung Cancer Trends of Age Adjusted Incidence and Mortality by Sex In OK



	2014	2015	2016	2017	2018	2019
Male Incidence	87.6	82.9	75.9	73.4	75.8	75.2
Female Incidence	60	58.7	55.1	55.6	59.5	57.5
Male Mortality	65.1	68	60.6	59.3	57.1	57.3
Female Mortality	43.5	42.9	40.3	37.2	38.7	38.2

GOAL = Stage Shift


5 Year Survival Rates for NSCLC

Localized

- ▶ 64% survival rate

Distant

- ▶ 8% survival rate



hillcrest

YOU ARE INVITED TO ATTEND A

HAPPY HOUR WITH RACHAEL PATTISON, D.O.,
UTICA PARK PULMONARY MEDICAL DIRECTOR AND
KRISTEN CROSS, LDCT, LUNG SCREENING PROGRAM RN
NAVIGATOR

NOV. 8, 2023

5:30 - 7 P.M.

NOTHING'S LEFT BREWERY
1502 E. 6TH ST.,
TULSA, OK, 74120

TOPIC: ION BIOPSY VS CT GUIDED BIOPSY
CONVERSATION WITH UPDATES IN THE LATEST
RECOMMENDATIONS, TECHNOLOGY, & CHANGING THE
FACE OF LUNG CANCER

PLEASE RSVP TO:
KRISTI RYAN
918-625-2989

Please Join Us!



Thank you!

Questions?

Rachael Pattison, DO
Pulmonary and Critical Care
Utica Park Pulmonary Medical Director